High-dose of human lymphoblastoid interferon in metastatic colorectal cancer: Clinical results and modification of biological responses

S. E. Krown, D. Mintzer, S. Cunningham-Rundles, D. Niedzwiecki, M. Krim, Avi Israel Einzig, J. L. Gabrilove, B. Shurgot, J. Gessula

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A total of 22 patients with advanced measurable colorectal carcinoma were treated with human lymphoblastoid interferon, 15 x 106 U/m2 im 3 times a week, in a trial designed to evaluate therapeutic activity, toxic effects, and biological response modification. One partial response (4.5% response rate) was observed which lasted 4 months. Sixty-eight percent of the patients required dose reduction for excessive toxicity, primarily constitutional symptoms. One patient developed phenobarbital toxicity, a previously undescribed side effect thought to be related to interferon-induced depression of hepatic microsomal enzymes required for drug metabolism. Treatment was associated with an increase in peripheral blood natural killer (NK) cell activity and the activity of an interferon-induced enzyme, 2'-5' oligoadenylate synthetase. The increase in NK cell activity was observed only in patients whose pretreatment NK cell activity was below normal. No induction of serum factors inducing differentiation of myeloid leukemic cell lines was documented. We conclude that human lymphoblastoid interferon, at the dose and schedule tested, has minimal antitumor activity as a single agent in advanced colorectal cancer and induces unacceptable toxicity in the majority of such patients. Recent literature suggesting a possible role for interferon alpha in combination with other drugs in the treatment of colorectal cancer is discussed.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalCancer Treatment Reports
Volume71
Issue number1
StatePublished - Apr 8 1987
Externally publishedYes

Fingerprint

Interferon-alpha
Colorectal Neoplasms
Natural Killer Cells
Interferons
Poisons
Myeloid Cells
Enzymes
Phenobarbital
Ligases
Pharmaceutical Preparations
Blood Cells
Appointments and Schedules
Therapeutics
Cell Line
Liver
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Krown, S. E., Mintzer, D., Cunningham-Rundles, S., Niedzwiecki, D., Krim, M., Einzig, A. I., ... Gessula, J. (1987). High-dose of human lymphoblastoid interferon in metastatic colorectal cancer: Clinical results and modification of biological responses. Cancer Treatment Reports, 71(1), 39-45.

High-dose of human lymphoblastoid interferon in metastatic colorectal cancer : Clinical results and modification of biological responses. / Krown, S. E.; Mintzer, D.; Cunningham-Rundles, S.; Niedzwiecki, D.; Krim, M.; Einzig, Avi Israel; Gabrilove, J. L.; Shurgot, B.; Gessula, J.

In: Cancer Treatment Reports, Vol. 71, No. 1, 08.04.1987, p. 39-45.

Research output: Contribution to journalArticle

Krown, SE, Mintzer, D, Cunningham-Rundles, S, Niedzwiecki, D, Krim, M, Einzig, AI, Gabrilove, JL, Shurgot, B & Gessula, J 1987, 'High-dose of human lymphoblastoid interferon in metastatic colorectal cancer: Clinical results and modification of biological responses', Cancer Treatment Reports, vol. 71, no. 1, pp. 39-45.
Krown, S. E. ; Mintzer, D. ; Cunningham-Rundles, S. ; Niedzwiecki, D. ; Krim, M. ; Einzig, Avi Israel ; Gabrilove, J. L. ; Shurgot, B. ; Gessula, J. / High-dose of human lymphoblastoid interferon in metastatic colorectal cancer : Clinical results and modification of biological responses. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 1. pp. 39-45.
@article{6394a111b5874de4a3988ed7cb4d59bf,
title = "High-dose of human lymphoblastoid interferon in metastatic colorectal cancer: Clinical results and modification of biological responses",
abstract = "A total of 22 patients with advanced measurable colorectal carcinoma were treated with human lymphoblastoid interferon, 15 x 106 U/m2 im 3 times a week, in a trial designed to evaluate therapeutic activity, toxic effects, and biological response modification. One partial response (4.5{\%} response rate) was observed which lasted 4 months. Sixty-eight percent of the patients required dose reduction for excessive toxicity, primarily constitutional symptoms. One patient developed phenobarbital toxicity, a previously undescribed side effect thought to be related to interferon-induced depression of hepatic microsomal enzymes required for drug metabolism. Treatment was associated with an increase in peripheral blood natural killer (NK) cell activity and the activity of an interferon-induced enzyme, 2'-5' oligoadenylate synthetase. The increase in NK cell activity was observed only in patients whose pretreatment NK cell activity was below normal. No induction of serum factors inducing differentiation of myeloid leukemic cell lines was documented. We conclude that human lymphoblastoid interferon, at the dose and schedule tested, has minimal antitumor activity as a single agent in advanced colorectal cancer and induces unacceptable toxicity in the majority of such patients. Recent literature suggesting a possible role for interferon alpha in combination with other drugs in the treatment of colorectal cancer is discussed.",
author = "Krown, {S. E.} and D. Mintzer and S. Cunningham-Rundles and D. Niedzwiecki and M. Krim and Einzig, {Avi Israel} and Gabrilove, {J. L.} and B. Shurgot and J. Gessula",
year = "1987",
month = "4",
day = "8",
language = "English (US)",
volume = "71",
pages = "39--45",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - High-dose of human lymphoblastoid interferon in metastatic colorectal cancer

T2 - Clinical results and modification of biological responses

AU - Krown, S. E.

AU - Mintzer, D.

AU - Cunningham-Rundles, S.

AU - Niedzwiecki, D.

AU - Krim, M.

AU - Einzig, Avi Israel

AU - Gabrilove, J. L.

AU - Shurgot, B.

AU - Gessula, J.

PY - 1987/4/8

Y1 - 1987/4/8

N2 - A total of 22 patients with advanced measurable colorectal carcinoma were treated with human lymphoblastoid interferon, 15 x 106 U/m2 im 3 times a week, in a trial designed to evaluate therapeutic activity, toxic effects, and biological response modification. One partial response (4.5% response rate) was observed which lasted 4 months. Sixty-eight percent of the patients required dose reduction for excessive toxicity, primarily constitutional symptoms. One patient developed phenobarbital toxicity, a previously undescribed side effect thought to be related to interferon-induced depression of hepatic microsomal enzymes required for drug metabolism. Treatment was associated with an increase in peripheral blood natural killer (NK) cell activity and the activity of an interferon-induced enzyme, 2'-5' oligoadenylate synthetase. The increase in NK cell activity was observed only in patients whose pretreatment NK cell activity was below normal. No induction of serum factors inducing differentiation of myeloid leukemic cell lines was documented. We conclude that human lymphoblastoid interferon, at the dose and schedule tested, has minimal antitumor activity as a single agent in advanced colorectal cancer and induces unacceptable toxicity in the majority of such patients. Recent literature suggesting a possible role for interferon alpha in combination with other drugs in the treatment of colorectal cancer is discussed.

AB - A total of 22 patients with advanced measurable colorectal carcinoma were treated with human lymphoblastoid interferon, 15 x 106 U/m2 im 3 times a week, in a trial designed to evaluate therapeutic activity, toxic effects, and biological response modification. One partial response (4.5% response rate) was observed which lasted 4 months. Sixty-eight percent of the patients required dose reduction for excessive toxicity, primarily constitutional symptoms. One patient developed phenobarbital toxicity, a previously undescribed side effect thought to be related to interferon-induced depression of hepatic microsomal enzymes required for drug metabolism. Treatment was associated with an increase in peripheral blood natural killer (NK) cell activity and the activity of an interferon-induced enzyme, 2'-5' oligoadenylate synthetase. The increase in NK cell activity was observed only in patients whose pretreatment NK cell activity was below normal. No induction of serum factors inducing differentiation of myeloid leukemic cell lines was documented. We conclude that human lymphoblastoid interferon, at the dose and schedule tested, has minimal antitumor activity as a single agent in advanced colorectal cancer and induces unacceptable toxicity in the majority of such patients. Recent literature suggesting a possible role for interferon alpha in combination with other drugs in the treatment of colorectal cancer is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0023102521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023102521&partnerID=8YFLogxK

M3 - Article

C2 - 3791267

AN - SCOPUS:0023102521

VL - 71

SP - 39

EP - 45

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -